Peptic Ulcer Disease
📧 Sign up to get email alerts when something new happens for Peptic Ulcer Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-05-21Clinical Trial Update: To Develop Methods for the Rehabilitation of Chronic Gastroduodenal Pathology in Children. [NA]
A pediatric trial update from Tashkent State Medical University describes developing rehabilitation methods for chronic gastroduodenal disea…
-
FDA approval · 2025-05-07FDA Approved: PANTOPRAZOLE SODIUM I.V. — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for pantoprazole sodium intravenous formulation from Sandoz Inc., expanding the product to include I…
-
FDA approval · 2025-04-15FDA Approved: ESOMEPRAZOLE MAGNESIUM — Original Application (Aurobindo Pharma Limited)
FDA approved an original application for Esomeprazole Magnesium from Aurobindo Pharma Limited, adding a generic esomeprazole magnesium produ…
-
FDA approval · 2025-03-31FDA Approved: BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE — Supplemental Application (H2-Pharma, LLC)
The FDA approved a supplemental application for the fixed-dose combination of bismuth subcitrate potassium, metronidazole, and tetracycline …
-
FDA approval · 2025-03-31FDA Approved: PANTOPRAZOLE SODIUM DELAYED-RELEASE DELAYED RELEASE — Original Application (Cipla USA Inc.)
FDA approves Cipla USA Inc.'s pantoprazole sodium delayed-release granules as an original generic pantoprazole product (ANDA 217458) for aci…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-03-05FDA Approved: ESOMEPRAZOLE MAGNESIUM FOR DELAYED-RELEASE ORAL SUSPENSION — Original Application (Torrent Pharmaceuticals Limited)
FDA approved Torrent Pharmaceuticals Limited's esomeprazole magnesium for delayed-release oral suspension via an original ANDA, confirming b…
-
FDA approval · 2025-03-05FDA Approved: ESOMEPRAZOLE MAGNESIUM FOR DELAYED-RELEASE ORAL SUSPENSION — Original Application (Torrent Pharmaceuticals Limited)
FDA approved Torrent Pharmaceuticals' esomeprazole magnesium delayed-release oral suspension via an original application, providing a generi…
-
FDA approval · 2024-12-19FDA Approved: LANSOPRAZOLE — Supplemental Application (Medcore LLC)
The FDA approved a supplemental application for lansoprazole from Medcore LLC, enabling a generic lansoprazole product to be marketed under …
-
FDA approval · 2024-12-19FDA Approved: LANSOPRAZOLE — Supplemental Application (NorthStar Rx LLC)
The FDA approved a supplemental application for lansoprazole submitted by NorthStar Rx LLC.
-
FDA approval · 2024-12-19FDA Approved: CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental ANDA for a generic chlordiazepoxide hydrochloride and clidinium bromide combination, manufactured by Ascend …
-
FDA approval · 2024-12-10FDA Approved: ESOMEPRAZOLE MAGNESIUM — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for esomeprazole magnesium from Ascend Laboratories, LLC, under an approved ANDA.
-
FDA approval · 2024-11-22FDA Approved: NAPROXEN AND ESOMEPRAZOLE MAGNESIUM — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA Inc.'s supplemental application for Naproxen and Esomeprazole Magnesium (ANDA 213699), establishing a generic…
-
FDA approval · 2024-11-12FDA Approved: CIMETIDINE — Original Application (Aurobindo Pharma Limited)
FDA approves Aurobindo Pharma Limited's original application for cimetidine (generic cimetidine), authorizing its marketing as a generic H2 …
-
FDA approval · 2024-11-08FDA Approved: GOOD NEIGHBOR PHARMACY OMEPRAZOLE — Supplemental Application (Amerisource Bergen)
FDA approved a supplemental application for Good Neighbor Pharmacy Omeprazole (omeprazole) submitted by Amerisource Bergen.
-
FDA approval · 2024-11-08FDA Approved: ACID REDUCER — Supplemental Application (WALGREEN CO.)
FDA approves a supplemental application for ACID REDUCER (omeprazole) from Walgreens Co., under ANDA206877.
-
FDA approval · 2024-11-07FDA Approved: CIMETIDINE — Original Application (Bionpharma Inc.)
FDA approved Bionpharma Inc.'s Original Application for cimetidine, enabling the marketing of a generic H2 blocker. The action establishes a…
-
FDA approval · 2024-09-19FDA Approved: BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE — Supplemental Application (H2-Pharma, LLC)
FDA approved a supplemental application for the combination drug Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride.…
-
CLINICAL_TRIALS trial_result · 2024-08-14Clinical Trial Update: Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg Chewable Tablets and Riopan 800 mg Chewable Tablets in Healthy Volunteers [NA]
This completed study evaluated whether Antareit 800 mg chewable tablets are pharmacodynamically equivalent to Riopan 800 mg chewable tablets…
-
FDA approval · 2024-08-01FDA Approved: PANTOPRAZOLE SODIUM — Original Application (Fresenius Kabi USA, LLC)
FDA approved Pantoprazole sodium from Fresenius Kabi USA as an original application (ANDA) generic product.
-
FDA approval · 2024-07-31FDA Approved: VOQUEZNA DUAL PAK — Supplemental Application (Phathom Pharmaceuticals Inc.)
FDA approved a supplemental application for Voquezna Dual Pak, a combination of vonoprazan fumarate and amoxicillin, to treat Helicobacter p…
-
FDA approval · 2024-07-17FDA Approved: ESOMEPRAZOLE MAGNESIUM — Supplemental Application (Somerset Therapeutics, LLC)
FDA approved a supplemental application for esomeprazole magnesium by Somerset Therapeutics, LLC.
-
FDA approval · 2024-07-08FDA Approved: BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE — Supplemental Application (H2-Pharma, LLC)
FDA approved a supplemental application for the antibiotic combination Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochl…
-
CLINICAL_TRIALS trial_result · 2024-07-08Clinical Trial Update: Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer [Phase 3]
Daewoong's Phase 3 trial DWP14012 for prevention of NSAIDs-induced peptic ulcers has completed.
-
FDA approval · 2024-07-08FDA Approved: CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE — Original Application (Winder Laboratories LLC)
FDA approved a generic version of the combination drug chlordiazepoxide hydrochloride and clidinium bromide from Winder Laboratories LLC. Th…
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases [NA]
A completed clinical trial evaluated the efficacy and safety of Hou Gu Mi Xi in patients with peptic ulcer disease.